Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Kristin L AyersTommy MullaneyXiang ZhouJane J LiuKyeryoung LeeMeng MaScott JonesLi LiArielle RedfernWhitney JappeZongzhi LiuHoward GoldsweigKamlesh K YadavNicholas HahnerMatthew DietzMichelle ZimmermanTony PrenticeScott NewmanRajwanth VeluswamyJuan WisniveskyFred R HirschWilliam K OhShuyu D LiEric E SchadtRong ChenPublished in: The oncologist (2021)
There is a significant underrepresentation of minority patients in randomized clinical trials, and this study demonstrates that real-world data can be used to investigate the impact of race and ethnicity on treatment response. In retrospective analysis of patients with advanced non-small cell lung cancer treated with programmed cell death-1 or programmed cell death-ligand 1 inhibitors, African American patients had significantly longer time-to-treatment discontinuation and longer overall survival. Analysis of real-world data can yield clinical insights and establish a more complete picture of medical interventions in routine clinical practice.
Keyphrases
- end stage renal disease
- advanced non small cell lung cancer
- clinical practice
- newly diagnosed
- african american
- ejection fraction
- healthcare
- electronic health record
- big data
- stem cells
- machine learning
- single cell
- physical activity
- clinical trial
- epidermal growth factor receptor
- patient reported outcomes
- data analysis
- young adults
- patient reported
- replacement therapy